Metrics

  • citations in SCIndeks: [1]
  • citations in CrossRef:0
  • citations in Google Scholar:[]
  • visits in previous 30 days:5
  • full-text downloads in 30 days:1

Contents

article: 10 from 17  
Back back to result list
2009, vol. 66, iss. 11, pp. 876-880
Risk factors for brain metastases after definitive chemoradiation for locally advanced non-small cell lung cancer
aClinical Center Kragujevac, Clinic of Pulmonology
bMilitary Medical Academy, Clinic for Pulmonology, Belgrade
cClinical Center of Serbia, Clinic for Pulmonology, Belgrade

emaildrmarinapetrovic@yahoo.com
Abstract
Background/Aim. As therapy for locally advanced nonsmall cell lung carcinoma (NSCLC) improves, brain metastases (BM) still remain a great problem. The aim of the study was to analyze risk factors for BM in patients with locally advanced NSCLC after chemoradiation therapy. Methods. Records for 150 patients with non-resectable stage IIIA/IIIB NSCLC treated with combined chemoradiation therapy were analyzed. All of them had negative brain metastases imaging result before the treatment. Incidence of BM was examined in relation to age, sex, histological type, stage, performance status scale of wellbeing of cancer patients, weight loss, chemotherapy regimen and chemotherapy timing. Results. One- and 2-year incidence rates of BM were 19 and 31%, respectively. Among pretreatment parameters, stage IIIB was associated with a higher risk of BM (p < 0.004) vs stage IIIA. Histologically, the patients with nonsquamous tumors had an exceptionally high 2-year BM risk rate of 32% (p < 0.02). Examining treatment-related parameters, 1-year and 2-year actuarial risk of BM were 27 and 39%, respectively, in the patients receiving chemotherapy before radiotherapy and 15 and 20%, respectively, when radiotherapy was not delayed (p < 0.03). On multivariate analysis, timing of chemotherapy (p < 0.05) and stage IIIA vs IIIB (p < 0.01) remained statistically significant. Conclusion. Patients with IIIB stage, nonsquamous NSCLC, particularly those receiving sequential chemotherapy, had significantly high BM rates.
References
Agboola, O., Benoit, B., Cross, P., da Silva, V., Esche, B., Lesiuk, H., Gonsalves, C. (1998) Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys, 42(1): 155-9
Andre, F., Grunenwald, D., Pujol, J.L., Girard, P., Dujon, A., Brouchet, L., Brichon, P.Y., Westeel, V., le Chevalier, T. (2001) Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: Should prophylactic cranial irradiation be reconsidered?. Cancer, 91(12): 2394-400
Arriagada, R., le Chevalier, T., Borie, F., Rivière, A., Chomy, P., Monnet, I., Tardivon, A., Viader, F., Tarayre, M., Benhamou, S. (1995) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst, 87(3): 183-90
Aupérin, A., Arriagada, R., Pignon, J.P., le Péchoux, C., Gregor, A., Stephens, R.J. (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. New England Journal of Medicine, 341(7): 476
Ceresoli, G.L., Reni, M., Chiesa, G., Carretta, A., Schipani, S., Passoni, P., Bolognesi, A., Zannini, P., Villa, E. (2002) Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: Risk factors analysis. Cancer, 95(3): 605-12
Chen, Y., Okunieff, P. (2004) Radiation and third-generation chemotherapy. Hematol Oncol Clin North Am, 18(1): 55-80
Cox, J.D., Scott, C.B., Byhardt, R.W., Emami, B., Russell, A.H., Fu, K.K., Parliament, M.B., Komaki, R., Gaspar, L.E. (1999) Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys, 43(3): 505-9
Curran, A.J., Scott, C., Langer, C., Komaki, R., Lee, J.S., Hauser, S., i dr. (2000) Phase III comparison of sequential vs concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol, 19: 1891a
Eberhardt, W., Wilke, H., Stuschke, M., Stamatis, G., Harstrick, A., Menker, H. (1997) 249 Preoperative chemotherapy and concurrent chemoradiotherapy based on hyperfractionated accelerated radiation followed by surgery in locally advanced (LAD) inoperable NSCLC stages IIIA and IIIB: The value of PCI. Lung Cancer, 18(1): 65
Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., Katagami, N., Ariyoshi, Y. (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol, 17(9): 2692-9
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., Mckenna, W.G., Byhardt, R. (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys, 37(4): 745-51
Gaspar, L.E., Chansky, K., Albain, K.S., Vallieres, E., Rusch, V., Crowley, J.J., Livingston, R.B., Gandara, D.R. (2005) Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: A retrospective review by the Southwest Oncology Group. J Clin Oncol, 23(13): 2955-61
Girard, N., Mornex, F. (2007) Chemoradiation for locally advanced nonsmall cell lung cancer. Cancer Radiother, 11, (1-2), 67-76, French
Gregor, A., Cull, A., Stephens, R.J., Kirkpatrick, J.A., Yarnold, J.R., Girling, D.J., Macbeth, F.R., Stout, R., Machin, D. (1997) Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European O. Eur J Cancer, 33(11): 1752-8
Jeremić, Branislav., Shibamoto, Y., Acimović, Ljubisa., Milisavljević, Slobodan. (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin etoposide for stage III non-small-cell lung cancer: A randomized study. Journal of Clinical Oncology, 14(4): 1065-1070
Law, A., Karp, D.D., Dipetrillo, T., Daly, B.T. (2001) Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma. Cancer, 92(1): 160-4
Lee, D.H., Han, J.Y., Cho, K.H., Pyo, H.R., Kim, H.Y., Yoon, S.J. (2005) Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 63(4): 1037-44
Mamon, H.J., Yeap, B.Y., Jänne, P.A., Reblando, J., Shrager, S., Jaklitsch, M.T., Mentzer, S., Lukanich, J.M., Sugarbaker, D.J., Baldini, E.H., Berman, S., Skarin, A., Bueno, R. (2005) High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol, 23(7): 1530-7
Martins, R.G. (2005) Treatment of locally advanced non-small cell lung cancer with combination of chemotherapy and radiation. Semin Respir Crit Care Med, 26(3): 273-7
Reboul, F.L. (2004) Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data. Hematol Oncol Clin North Am, 18(1): 41-53
Robnett, T.J., Machtay, M., Stevenson, J.P., Algazy, K.M., Hahn, S.M. (2001) Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol, 19(5): 1344-9
Ryan, G.F., Ball, D.L., Smith, J.G. (1995) Treatment of brain metastases from primary lung cancer. Int J Radiat Oncol Biol Phys, 31(2): 273-8
Sause, W., Kolesar, P., Taylor, S.I.V., Johnson, D., Livingston, R., Komaki, R., Emami, B., Curran, W., Byhardt, R., Dar, A.R., Turrisi, A. (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest, 117(2): 358-64
Sheehan, J.P., Sun, M., Kondziolka, D., Flickinger, J., Lunsford, D.L. (2002) Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg, 97(6): 1276-81
Stinchcombe, T.E., Fried, D., Morris, D.E., Socinski, M.A. (2006) Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer. Oncologist, 11(7): 809
Vokes, E.E., Gordon, G.S., Rudin, C.M., Mauer, A.M., Watson, S., Krauss, S., Arrieta, R., Golomb, H.M., Hoffman, P.C. (2001) A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Invest New Drugs, 19(4): 329-33
 

About

article language: Serbian
document type: Original Paper
DOI: 10.2298/VSP0911876P
published in SCIndeks: 24/11/2009